Related Experiment Video
Updated: Dec 21, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells
Huaijin Zhang1, Yuling Chen1, Xiaohui Liu1
1MOE Key Laboratory of Bioinformatics, Center for Synthetic and Systematic Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.
Abstract:
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor with poor prognosis. Temozolomide (TMZ) is the standard chemotherapy for glioblastoma treatment, but TMZ resistance significantly compromises its efficacy. In the present study, we generated a TMZ-resistant cell line and identified that mitochondrial dysfunction was a novel factor contributing to TMZ resistance though multi-omics analyses and energy metabolism analysis. Furthermore, we found that rotenone treatment induced TMZ resistance to a certain level in glioblastoma cells. Notably, we further demonstrated that elevated Ca2+ levels and JNK-STAT3 pathway activation contributed to TMZ resistance and that inhibiting JNK or STAT3 increases susceptibility to TMZ. Taken together, our results indicate that co-administering TMZ with a JNK or STAT3 inhibitor holds promise as a potentially effective treatment for glioblastoma.
Insights
Glioblastoma (GBM) treatment resistance can be overcome. Mitochondrial dysfunction and elevated Ca2+ levels contribute to resistance, suggesting combined therapies targeting JNK or STAT3 pathways may improve glioblastoma outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Mitochondrial Medicine
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Temozolomide (TMZ) is the standard chemotherapy, but resistance limits its effectiveness.
Purpose of the Study:
- To investigate novel mechanisms of TMZ resistance in GBM.
- To identify potential therapeutic strategies to overcome TMZ resistance.
Main Methods:
- Generation of a TMZ-resistant GBM cell line.
- Multi-omics and energy metabolism analyses.
- Investigation of the role of mitochondrial dysfunction, calcium levels, and JNK-STAT3 pathway.
Main Results:
- Mitochondrial dysfunction identified as a novel contributor to TMZ resistance.
- Rotenone treatment partially induced TMZ resistance.
- Elevated Ca2+ levels and activated JNK-STAT3 pathway were linked to TMZ resistance.
- Inhibiting JNK or STAT3 enhanced GBM cell susceptibility to TMZ.
Conclusions:
- Mitochondrial dysfunction, elevated Ca2+, and JNK-STAT3 pathway activation are key factors in GBM TMZ resistance.
- Co-administering TMZ with JNK or STAT3 inhibitors shows promise for overcoming treatment resistance in glioblastoma.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway
Mitochondrial Membranes

